Racial differences in endometrial cancer molecular portraits in The Cancer Genome Atlas

Oncotarget

Volumn 9, Issue 24, 2018, Pages 17093-17103

  Guttery, David S ^a   Blighe, Kevin ^a   Polymeros, Konstantinos ^a,b   Paul Symonds, R ^a   Macip, Salvador ^a   Moss, Esther L ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Endometrial cancer; Ethnicity; Somatic copy number aberrations; TCGA

Indexed keywords

EID: 85044789836     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.24907     Document Type: Article

References (45)

1. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017
2. Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev. 2015; 24:1407-1415
3. Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev. 2013; 22:233-241
4. Chatterjee S, Gupta D, Caputo TA, Holcomb K. Disparities in gynecological malignancies. Front Oncol. 2016; 6:36
5. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol. 2007; 165:262-270
6. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among african americans in the united states. Gynecol Oncol. 2013; 130:652-659
7. Maxwell GL, Risinger JI, Hayes KA, Alvarez AA, Dodge RK, Barrett JC, Berchuck A. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000; 6:2999-3005
8. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998; 4:3005-3010
9. Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer. 2000; 89:1758-1764
10. Clifford SL, Kaminetsky CP, Cirisano FD, Dodge R, Soper JT, Clarke-Pearson DL, Berchuck A. Racial disparity in overexpression of the p53 tumor suppressor gene in stage i endometrial cancer. Am J Obstet Gynecol. 1997; 176:S229-232
11. Cote ML, Atikukke G, Ruterbusch JJ, Olson SH, Sealy-Jefferson S, Rybicki BA, Alford SH, Elshaikh MA, Gaba AR, Schultz D, Haddad R, Munkarah AR, Ali-Fehmi R. Racial differences in oncogene mutations detected in earlystage low-grade endometrial cancers. Int J Gynecol Cancer. 2012; 22:1367-1372
12. Zhang MM, Cheung MK, Osann K, Lee MM, Gomez SS, Whittemore AS, Husain A, Teng NN, Chan JK. Improved survival of asians with corpus cancer compared with whites: an analysis of underlying factors. Obstet Gynecol. 2006; 107:329-335
13. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67-73
14. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, et al. Screening for lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66:7810-7817
15. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, Pritchard CC. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014; 147:1308-1316
16. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR; Gynecologic Oncology Groups. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a gynecologic oncology group study. Cancer. 2006; 107:2197-2205
17. Oliver KE, Enewold LR, Zhu K, Conrads TP, Rose GS, Maxwell GL, Farley JH. Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol. 2011; 123:76-81
18. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC, Program NIHISCCS, Hieter P, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012; 44:1310-1315
19. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol. 2011; 223:116-126
20. Song H, Hollstein M, Xu Y. P53 gain-of-function cancer mutants induce genetic instability by inactivating atm. Nat Cell Biol. 2007; 9:573-580
21. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013; 20:898-909
22. Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H, Zou W, Fang JY. Unequal prognostic potentials of p53 gain-offunction mutations in human cancers associate with drugmetabolizing activity. Cell Death Dis. 2014; 5:e1108
23. Goh JY, Feng M, Wang W, Oguz G, Yatim S, Lee PL, Bao Y, Lim TH, Wang P, Tam WL, Kodahl AR, Lyng MB, Sarma S, et al. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nat Med. 2017; 23:1319-1330
24. Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 2014; 4:89-115
25. Haesen D, Abbasi Asbagh L, Derua R, Hubert A, Schrauwen S, Hoorne Y, Amant F, Waelkens E, Sablina A, Janssens V. Recurrent PPP2R1A mutations in uterine cancer act through a dominant-negative mechanism to promote malignant cell growth. Cancer Res. 2016; 76:5719-5731
26. Jeong AL, Han S, Lee S, Su Park J, Lu Y, Yu S, Li J, Chun KH, Mills GB, Yang Y. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRCJNK-c-Jun pathway. Sci Rep. 2016; 6:27391
27. Guenin S, Mouallif M, Deplus R, Lampe X, Krusy N, Calonne E, Delbecque K, Kridelka F, Fuks F, Ennaji MM, Delvenne P. Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis. PLoS One. 2012; 7:e42704
28. Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M, Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother. 2013; 67:240-245
29. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK, Mertani HC, Zhu T, Liu D, et al. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology. 2009; 150:4473-4483
30. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA. Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006; 24:2261-2267
31. Sunagawa M, Yamaguchi J, Kokuryo T, Ebata T, Yokoyama Y, Sugawara G, Nagino M. Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. Pancreatology. 2017; 17:782-787
32. Faigenbaum R, Haklai R, Ben-Baruch G, Kloog Y. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the ras inhibitor salirasib. Oncotarget. 2013; 4:316-328
33. Yang XW, Shen GZ, Cao LQ, Jiang XF, Peng HP, Shen G, Chen D, Xue P. Microrna-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of foxo1. BMC Cancer. 2014; 14:909
34. Kong XX, Lv YR, Shao LP, Nong XY, Zhang GL, Zhang Y, Fan HX, Liu M, Li X, Tang H. HBx-induced MiR-1269b in NF-kappaB dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells. J Transl Med. 2016; 14:189
35. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009; 41:112-117
36. Rhees J, Arnold M, Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer. 2014; 13:219-225
37. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357:409-413
38. Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget. 2017; 8:40152-40168. https://doi. org/10.18632/oncotarget.10308
39. Team RDC. (2017). R: A language and environment for statistical computing. (Vienna, Austria: R Foundation for Statistical Computing)
40. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15:550
41. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016; 32:2847-2849
42. Morganella S, Pagnotta SM, Ceccarelli M. Finding recurrent copy number alterations preserving within-sample homogeneity. Bioinformatics. 2011; 27:2949-2956
43. Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A, Huber W. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics. 2005; 21:3439-3440
44. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ. Software for computing and annotating genomic ranges. PLoS Comput Biol. 2013; 9:e1003118
45. Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B. Survcomp: an r/bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011; 27:3206-3208